Kazia Therapeutics (KZIA) vs OnKure Therapeutics (OKUR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Kazia Therapeutics (KZIA) has outperformed OnKure Therapeutics (OKUR) over the past year, gaining 24.4% versus a loss of 24.3%. Over five years, OKUR leads with a -96.4% price change compared with -98.3% for KZIA. Kazia Therapeutics is the larger company by market cap ($102.0 million vs $97.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KZIA | OKUR |
|---|---|---|
| Share price | $8.93 | $2.41 |
| Market cap | $102.04M | $97.60M |
| 1-day change | +1.25% | +4.78% |
| YTD return | +29.61% | -20.69% |
| 1-year return | +24.37% | -24.34% |
| 5-year return | -98.30% | -96.43% |
| EPS (TTM) | $-6.85 | $-3.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.40 | $5.38 |
| 52-week low | $4.86 | $2.13 |
| Distance from 52-week high | -48.68% | -55.20% |
| Analyst consensus | none | none |
| Avg. price target upside | +216.46% | +543.15% |
| Average volume | 262.41K | 216.96K |
| Shares outstanding | 11.43M | 40.50M |
| Employees | 6 | 45 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KZIA has outperformed OKUR by 48.7 percentage points over the past year.
About Kazia Therapeutics
KZIA stock →Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
About OnKure Therapeutics
OKUR stock →OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 45 employees
KZIA vs OKUR FAQ
Which is bigger, Kazia Therapeutics or OnKure Therapeutics?
Kazia Therapeutics (KZIA) is larger, with a market capitalization of $102.04M compared with $97.60M for OnKure Therapeutics (OKUR).
Which stock has performed better over the past year, KZIA or OKUR?
KZIA returned +24.37% over the past 12 months, compared with -24.34% for OKUR (price return, excluding dividends). Past performance does not predict future results.
Are Kazia Therapeutics and OnKure Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.